169 related articles for article (PubMed ID: 22170881)
1. Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.
Aasly JO; Shi M; Sossi V; Stewart T; Johansen KK; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Kim HM; Leverenz JB; Ginghina C; Armaly J; Edwards KL; Snapinn KW; Stoessl AJ; Zhang J
Neurology; 2012 Jan; 78(1):55-61. PubMed ID: 22170881
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
3. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
[TBL] [Abstract][Full Text] [Related]
4. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
[TBL] [Abstract][Full Text] [Related]
5. DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.
Shi M; Furay AR; Sossi V; Aasly JO; Armaly J; Wang Y; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Leverenz JB; Stoessl AJ; Zhang J
Neurobiol Aging; 2012 Apr; 33(4):836.e5-7. PubMed ID: 22019052
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
7. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.
Ichinose H; Inoue KI; Arakawa S; Watanabe Y; Kurosaki H; Koshiba S; Hustad E; Takada M; Aasly JO
J Neural Transm (Vienna); 2018 Jan; 125(1):45-52. PubMed ID: 28864907
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease.
Zhang J; Mattison HA; Liu C; Ginghina C; Auinger P; McDermott MP; Stewart T; Kang UJ; ; Cain KC; Shi M
Acta Neuropathol; 2013 Nov; 126(5):671-82. PubMed ID: 23644819
[TBL] [Abstract][Full Text] [Related]
11. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
12. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Adams JR; van Netten H; Schulzer M; Mak E; Mckenzie J; Strongosky A; Sossi V; Ruth TJ; Lee CS; Farrer M; Gasser T; Uitti RJ; Calne DB; Wszolek ZK; Stoessl AJ
Brain; 2005 Dec; 128(Pt 12):2777-85. PubMed ID: 16081470
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
16. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
17. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.
Shi M; Bradner J; Hancock AM; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Kim HM; Leverenz JB; Montine TJ; Ginghina C; Kang UJ; Cain KC; Wang Y; Aasly J; Goldstein D; Zhang J
Ann Neurol; 2011 Mar; 69(3):570-80. PubMed ID: 21400565
[TBL] [Abstract][Full Text] [Related]
19. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease.
Compta Y; Ezquerra M; Muñoz E; Tolosa E; Valldeoriola F; Rios J; Cámara A; Fernández M; Buongiorno MT; Marti MJ
Neurosci Lett; 2011 Jan; 487(2):169-73. PubMed ID: 20951764
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]